AzTrials
AzTrials

Surgical WoundNCT04307355

Continuous Diffusion of Oxygen Treatment for Incision Wounds

A study testing Transcu O2®, Tegaderm and Silagen in people with Surgical Wound and Breast Surgery, run by Baylor College of Medicine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is an exploratory randomized controlled trial study to test feasibility, acceptability, and proof of concept efficacy of Continuous Diffusion of Oxygen (CDO) adjunct therapy for decreasing healing time and reducing tissue necrosis post breast reconstruction. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Surgical Wound, Breast Surgery, Mammoplasty
What is being tested?
Transcu O2®, Tegaderm and Silagen
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
23 participants
Where
1 siteUnited States
Study dates
1 Jun 2021to 28 Aug 2023
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18-85 years of age
  • Ability to provide informed consent
  • Presence of a wound due to surgical intervention and closure
  • Subject or responsible caregiver is willing and able to maintain the required Continuous Diffusion of Oxygen (CDO) system (if assigned to the intervention group) and applicable dressing changes

Who cannot join

  • Active Drug/alcohol abuse (or history of drug/alcohol abuse in last 1 month)
  • Dementia or severely impaired cognitive function
  • excessive lymphedema
  • presence of active infection
  • subject has a history of or any intercurrent illnesses or conditions that would compromise the safety of the subject according to judgement of a qualified wound specialist

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Baylor College of Medicine

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Evaluation of Oxygen Delivery With TransCu O2 to Study Success Rate of Surgically Closed Wounds

This is an exploratory randomized controlled trial study to test feasibility, acceptability, and proof of concept efficacy of Continuous Diffusion of Oxygen (CDO) adjunct therapy for decreasing healing time and reducing tissue necrosis post breast reconstruction. The investigator will assess the benefit of this novel adjunct therapy on successful closure, tissue oxygenation, scar appearance, and patients centered outcomes including perception of benefit, pain, sleep quality, and quality of life.

Eligible subjects will be randomly (ratio 1:1) assigned to either intervention group (IG) or control group (CG) and will be followed for four weeks. Both groups will receive standard of care for wound treatment. IG will also receive CDO adjunct therapy using a novel dressing, which facilitates continuously supplies oxygen to the wound inside the wound dressing using a portable device named TransCu O2.

The study device TransCu O2® is a Class II medical device which has US Food and Drug Administration (FDA) 510(k) clearance, CE-Mark approval and a Health Canada license for the treatment of wounds. Outcomes will be assessed on weekly-basis up to 4 weeks.

Read the detailed description

Surgical wound complications such as infection, dehiscence, necrotic tissue, surgical revision, and poor cosmesis are unfortunately highly prevalent in patients post breast reconstruction. In particular, necrosis/ischemia post breast reconstruction because of poor blood circulation is highly prevalent and is estimated to be occurring in up to 75% of cases leading to excessive scar formation. Some factors such as active smoking or an underlying disease such as diabetes and history of radiation therapy could increase the likelihood of excessive scar and/or necrosis.

In most cases surgical wounds are managed with a simple island dressing, wool padding and a light retention bandage. It could be argued that such low cost, traditional dressings are adequate for most surgical wounds. However, patients with poor tissue blood circulation often require modern wound care products that offer additional benefits, in particular among those with vascular and poor tissue oxygenation problem. Poor tissue oxygenation and poor skin perfusion could lead to surgical wound complications such as wound inflection, tissue necrosis, pain, trauma and untimely surgical revision. In particular, the presence of non-viable necrotic tissue is significant as it can be responsible for delaying healing, prolonging the inflammatory response, mechanically obstructing contraction and impeding re-epithelialisation. It also provides a focus for wound infection and surgical revision.

Even after successful healing, necrotic tissue could still lead to excessive scar formation. Many of these scars can be problematic, being aesthetically unpleasant and causing discomfort. Blood supply is a significant factor in wound healing, and area of the skin with rich supply of vasculature is known to heal with finer scars. Several studies have demonstrated that mild hypoxia (lack of transcutaneous oxygen) is present in early scars, moderate hypoxia in proliferative scars, and severe hypoxia in regressive scars. Oxygen levels then return to normal in mature scars, which is consistent along with the dynamic change in microvessel density. Therefore level of transcutaneous oxygen could be a determinant factor in formation of excessive scar formation.

Continuous Diffusion of Oxygen (CDO) is a treatment modality that delivers pure oxygen to wounds using the same basic mechanism as breathing, namely direct diffusion into the wound from a moist surface. Because impaired blood flow results in impaired oxygen supply to incisional wounds, investigators have researched the potential of oxygen saturation, or supersaturation, to reinitiate or even accelerate wound healing. Oxygen has been shown to result in not only faster wound closure, yet also better strength of repair and higher organization of collagen, which in turn can result in lower wound recidivism and better scar appearance.

In this feasibility and proof of concept study, The investigator plan to investigate the effects of oxygen on incisional wound repair and scarring after mastectomy and breast reconstruction. The investigator will use a device (TransCu O2® Oxygen Delivery System ) which continuously supplies oxygen to the wound inside the wound dressing. The device the investigator used, the TransCu O2 System, (EO2 Concepts®, San Antonio, TX) is small, wearable and silent. The system is FDA-approved and CDO therapy has been the subject of a growing body of clinical experience and scientific investigations demonstrating good results. The therapy is similar in theory to the intermittent application of oxygen through Hyperbaric Oxygen (HBO) and Topical Oxygen (TO), with a few key differences summarizing in the following:

  1. CDO provides continuous therapy, providing ~twenty-fold longer time of oxygen delivery versus intermittent therapies that are only applied 90 minutes a day. 2) CDO allows for full patient mobility during treatment, thereby reducing the risk of non-compliance and reducing overall costs

The investigator have successfully used CDO therapy to reduce likelihood of tissue necrosis after surgical closure post lower extremity amputation as well as post parathyroid surgery, in which over 20 subjects were recruited and no adverse outcomes were reported. The investigator plan to extend our study to determine whether CDO therapy would show decreased healing time and better scar cosmesis early on for standardized incisional wounds such as breast reconstruction. The investigator hypothesis that using CDO will reduce the likelihood of necrotic tissue as well as severe incisional scar post-surgical closure by improving transcutaneous oxygen levels during wound healing process. The investigator will examine the validity of this hypothesis using a pilot randomized controlled trial using a convenient sample of 40 people (20 subjects per arm) after mastectomy and breast reconstruction surgery.

Being tested
Transcu O2®, Tegaderm, Silagen
Keywords
Infection, Dehiscense, Tissue infection, Surgical Revision, Scar tissue, Wound Closure
Medical subject headings
Surgical Wound, Infections, Cicatrix

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcu O2®Device

    Breasts randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.

  • TegadermOther

    A 10 cm × 12 cm Tegaderm TM Film adhesive (3M Healthcare, Minnesota).

  • SilagenOther

    A 10 cm × 12 cm silicon sheet (Silagen, New Medical Technology, Inc, Illinois).

Study groups in NCT04307355
Study groupRoleWhat they receive
Direct Continuous Diffusion of Oxygen (dCDO)Active comparatorOne of the participant's breasts will be provided with a Transcu O2 ® Oxygen delivery system and 4x4 dressing at the surgical site for 4 weeks as supportive care. The 4x4 dressing will be attached to breast using Tegaderm adhesive.
Receives: Device: Transcu O2®; Other: Tegaderm
ControlNo interventionOne of the participant's breasts will receive a standard-of-care at the surgical site and will be followed for 4 weeks.
Silicon Continuous Diffusion of Oxygen (sCDO)Active comparatorOne of the participant's breasts will be provided with a Transcu O2 ® Oxygen delivery system and 4x4 dressing at the surgical site for 4 weeks as supportive care. The 4x4 dressing will be attached to breast using Silagen adhesive.
Receives: Device: Transcu O2®; Other: Silagen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wound Size at 4 Weeks

    Wound size will be traced and quantified using a wound imaging system (Snapshot, Kent Imaging)

    Measured: 4 weeks

  2. Incidence of Wound Complication at 4 Weeks

    Complication is described as infection, dehiscence, and/or necrotic tissue

    Measured: 4 weeks

Secondary outcomes (4)
  1. Presence of Scar Tissue

    Scar tissue presence will be assessed by simple view.

    Measured: 4 weeks

  2. Change in DeoxyHB From Baseline to 4 Weeks

    DeoxyHb at the T-Junction of each breast will be assessed using near-infrared spectroscopy (Snapshot, Kent Imaging). DeoxyHb is measured as a fraction ranging from 0 to 1. The reported values below are the estimate percent change from the baseline visit to the 4th week visit.

    Measured: Baseline to 4 weeks

  3. Self-reported Pain at Week 4

    Pain will be assessed with visual analogue scale from 0 to 10 where 10 is the worst pain ever. At the final visit, patients were asked to rate their pain on this scale using the POSAS (Patient and Observer Scar Assessment Scale) questionnaire. An average of this score was taken across each group.

    Measured: At 4 weeks

  4. Change in Tissue Oxygen Saturation (SatO2) From Baseline to 4 Weeks

    SatO2 at the T-Junction of each breast will be assessed using near-infrared spectroscopy (Snapshot, Kent Imaging). SatO2 is measured as a fraction ranging from 0 to 1. The reported values below are the estimate percent change from the baseline visit to the 4th week visit.

    Measured: Baseline to 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2020
  2. Study start1 Jun 2021
  3. Primary completion28 Aug 2023
  4. Study completion28 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Each participant will act as their own control in this model. One of the participant's breasts will receive the intervention dressing while the other intervention breast will receive the standard of care.
Masking
None (open label)
Enrolment
23 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04307355
Sponsor's protocol ID
H-46332
Status last verified
Jan 2025
First submitted
11 Mar 2020
Last updated
6 Feb 2025
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Publications

  • Zulbaran-Rojas A, Bara RO, Lee M, Flores-Camargo A, Mishra R, Winocour S, Thompson A, Najafi B. Optimizing Tissue Oxygenation in Reduction Mammoplasty: The Role of Continuous Diffusion of Oxygen: A Feasibility Pilot Randomized Controlled Trial. J Surg Res. 2023 Dec;292:113-122. doi: 10.1016/j.jss.2023.07.035. Epub 2023 Aug 21.

    PubMed 37611440

Questions about this trial

What is this clinical trial studying?

A study testing Transcu O2®, Tegaderm and Silagen in people with Surgical Wound and Breast Surgery, run by Baylor College of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Feb 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wound Size at 4 Weeks (time frame: 4 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04307355, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in